WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
JP6219832B2
(en)
|
2011-10-17 |
2017-10-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
Intracellular delivery
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
AU2014306423B2
(en)
|
2013-08-16 |
2019-04-18 |
Massachusetts Institute Of Technology |
Selective delivery of material to cells
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
PT3066201T
(en)
|
2013-11-07 |
2018-06-04 |
Massachusetts Inst Technology |
Crispr-related methods and compositions with governing grnas
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
MA40253A
(en)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Engineered cells for adoptive cell therapy
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
KR20170074235A
(en)
|
2014-10-31 |
2017-06-29 |
메사추세츠 인스티튜트 오브 테크놀로지 |
Delivery of biomolecules to immune cells
|
US20170335331A1
(en)
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
CN113897285A
(en)
|
2014-11-14 |
2022-01-07 |
麻省理工学院 |
Disruption and field-effected delivery of compounds and compositions into cells
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
US11125739B2
(en)
|
2015-01-12 |
2021-09-21 |
Massachusetts Institute Of Technology |
Gene editing through microfluidic delivery
|
WO2016154596A1
(en)
*
|
2015-03-25 |
2016-09-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
MX2017012407A
(en)
*
|
2015-03-27 |
2018-03-07 |
Harvard College |
Modified t cells and methods of making and using the same.
|
US10968426B2
(en)
|
2015-05-08 |
2021-04-06 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
CA2986310A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
AU2016262521A1
(en)
*
|
2015-05-11 |
2017-12-14 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
|
JP6949728B2
(en)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells
|
AU2016276702B2
(en)
|
2015-06-09 |
2022-07-28 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for improving transplantation
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
CA2988996A1
(en)
|
2015-07-09 |
2017-01-12 |
Massachusetts Institute Of Technology |
Delivery of materials to anucleate cells
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
US10906951B2
(en)
|
2015-07-29 |
2021-02-02 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
AU2016300128B2
(en)
|
2015-07-29 |
2022-03-17 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
EP3344575B1
(en)
|
2015-09-04 |
2020-04-15 |
SQZ Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
EP3362571A4
(en)
|
2015-10-13 |
2019-07-10 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
JP7109784B2
(en)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Evolved Cas9 protein for gene editing
|
CN109312338B
(en)
|
2015-10-30 |
2022-09-27 |
爱迪塔斯医药公司 |
CRISPR/CAS related methods and compositions for treating herpes simplex virus
|
CN108699557A
(en)
*
|
2015-12-04 |
2018-10-23 |
诺华股份有限公司 |
Composition for oncology to be immunized and method
|
CN108779475A
(en)
*
|
2016-01-12 |
2018-11-09 |
Sqz生物技术公司 |
The Intracellular delivery of compound
|
US11530253B2
(en)
|
2016-02-25 |
2022-12-20 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
|
MX2018010484A
(en)
*
|
2016-03-04 |
2019-01-10 |
Editas Medicine Inc |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy.
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
KR20190080825A
(en)
*
|
2016-03-21 |
2019-07-08 |
다나-파버 캔서 인스티튜트 인크. |
T-cell dysfunction state-specific gene expression regulators and their uses
|
EP3445375A1
(en)
*
|
2016-04-22 |
2019-02-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four
|
CN107304434A
(en)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
A kind of difunctional novel carriers of immune cell therapy
|
CN116850305A
(en)
*
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
Genetically engineered cells and methods of making same
|
EP3452055A4
(en)
*
|
2016-05-06 |
2019-11-06 |
Tod M. Woolf |
Improved methods for genome editing with and without programmable nucleases
|
DK3476865T3
(en)
|
2016-06-28 |
2023-12-18 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
PROCEDURE FOR CONSTRUCTION OF PD-1 GENE-MODIFIED HUMANIZED ANIMAL MODEL AND USE THEREOF
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
CN110214183A
(en)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
Adenosine nucleobase editing machine and application thereof
|
EP3494132A4
(en)
*
|
2016-08-03 |
2020-03-18 |
Washington University |
Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
CA3033788A1
(en)
|
2016-08-17 |
2018-02-22 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
CN110139873A
(en)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
HPV specific binding molecules
|
EP4190335A1
(en)
|
2016-10-13 |
2023-06-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
JP7181862B2
(en)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
Tumor-infiltrating lymphocytes and methods of treatment
|
AU2017347848A1
(en)
*
|
2016-10-27 |
2019-05-23 |
Intima Bioscience, Inc. |
Viral methods of making genetically modified cells
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
EP3546577B1
(en)
|
2016-11-28 |
2021-11-17 |
Napajen Pharma, Inc. |
Chemically-modified sirna
|
MA46998A
(en)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
PRODUCTION OF MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
CN110191955B
(en)
|
2016-12-13 |
2024-05-31 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Method for exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
CN110913870A
(en)
*
|
2016-12-30 |
2020-03-24 |
细胞结构公司 |
Genetically modified natural killer cells
|
CN110520156A
(en)
*
|
2017-01-29 |
2019-11-29 |
唐泽群 |
For the immunoregulation method of exogenous antigen and/or autoantigen
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
US10828330B2
(en)
*
|
2017-02-22 |
2020-11-10 |
IO Bioscience, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(en)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Base-editing factor from cytosine to guanine
|
WO2018175636A2
(en)
*
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
WO2018191490A1
(en)
*
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
AU2018367896B2
(en)
|
2017-05-12 |
2023-06-01 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
EP3635104A1
(en)
|
2017-06-09 |
2020-04-15 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
KR20200018645A
(en)
|
2017-06-15 |
2020-02-19 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
Targeted non-viral DNA insertion
|
CA3064807A1
(en)
*
|
2017-06-20 |
2018-12-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Method for knocking out target gene in t cell in vitro and crrna used in the method
|
SG10201705285SA
(en)
*
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
US20200140896A1
(en)
*
|
2017-06-30 |
2020-05-07 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
EP3676376A2
(en)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
CN111148533A
(en)
|
2017-09-19 |
2020-05-12 |
麻省理工学院 |
Compositions for chimeric antigen receptor T cell therapy and uses thereof
|
KR20200104284A
(en)
|
2017-10-03 |
2020-09-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
HPV-specific binding molecule
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric pd-1
|
CN111757937A
(en)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
Use of adenosine base editor
|
IL274179B2
(en)
|
2017-10-27 |
2024-02-01 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
JP2021502077A
(en)
*
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
|
CN111655292A
(en)
*
|
2017-12-07 |
2020-09-11 |
旗舰先锋创新V股份有限公司 |
Cellular biologicals and therapeutic uses thereof
|
WO2019118508A1
(en)
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
WO2019118793A2
(en)
*
|
2017-12-14 |
2019-06-20 |
Ezy Biotech Llc |
Subject-specific tumor inhibiting cells and the use thereof
|
DK3765615T3
(en)
|
2018-03-14 |
2023-08-21 |
Arbor Biotechnologies Inc |
NEW ENZYMES AND SYSTEMS FOR TARGETING CRISPR DNA
|
EP3765094A4
(en)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
CA3093915A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
RU2020136054A
(en)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
T-CELLS EXPRESSING RECOMBINANT RECEPTOR, CORRESPONDING POLYNUCLEOTIDES AND METHODS
|
CN112566698A
(en)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T cell receptor and engineered cells expressing the same
|
BR112020020245A2
(en)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
|
CN112384621A
(en)
*
|
2018-04-13 |
2021-02-19 |
西格马-奥尔德里奇有限责任公司 |
Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins
|
KR20210016353A
(en)
|
2018-04-27 |
2021-02-15 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
Rapamycin-resistant cells
|
BR112020022879A2
(en)
|
2018-05-11 |
2021-02-23 |
Crispr Therapeutics Ag |
methods and compositions for cancer treatment
|
CN108866004A
(en)
*
|
2018-06-26 |
2018-11-23 |
奥妙生物技术(广州)有限公司 |
The T cell and its construction method that SHP-1 is knocked out
|
CN112823011A
(en)
*
|
2018-07-09 |
2021-05-18 |
加利福尼亚大学董事会 |
Gene targets for T cell-based immunotherapy
|
WO2020022802A1
(en)
*
|
2018-07-25 |
2020-01-30 |
주식회사 툴젠 |
Genome editing for treating autoimmune disease
|
WO2020022803A1
(en)
*
|
2018-07-26 |
2020-01-30 |
주식회사 툴젠 |
Gene editing of anticoagulants
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
EP3849305B1
(en)
*
|
2018-09-11 |
2023-12-13 |
Board of Regents, The University of Texas System |
A genetic mouse model of autoimmune adverse events and immune checkpoint blockade therapy
|
JP2022502037A
(en)
|
2018-09-28 |
2022-01-11 |
マサチューセッツ インスティテュート オブ テクノロジー |
Immunomodulatory molecules localized to collagen and their methods
|
WO2020072059A1
(en)
*
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
BR112021007025A2
(en)
*
|
2018-10-16 |
2021-08-03 |
Intellia Therapeutics, Inc. |
compositions and methods for immunotherapy
|
AU2019372642B2
(en)
*
|
2018-10-29 |
2023-11-23 |
China Agricultural University |
Novel CRISPR/Cas12f enzyme and system
|
CN113544266A
(en)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
CRISPR-associated transposase systems and methods of use thereof
|
WO2020157750A1
(en)
*
|
2019-01-28 |
2020-08-06 |
Bar Ilan University |
Combinations, nanoparticles and methods for controlling natural killer cell activation and function
|
MX2021009742A
(en)
|
2019-02-15 |
2021-12-10 |
Editas Medicine Inc |
Modified natural killer (nk) cells for immunotherapy.
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
CN113966401A
(en)
|
2019-04-10 |
2022-01-21 |
犹他大学研究基金会 |
HTRA1 modulation for the treatment of AMD
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
MX2021013219A
(en)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods.
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
CN114206936A
(en)
*
|
2019-06-14 |
2022-03-18 |
2赛文缇生物公司 |
Compositions and methods for treating cancer
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
WO2021150078A1
(en)
*
|
2020-01-23 |
2021-07-29 |
주식회사 강스템바이오텍 |
Off-the-shelf stem cells and immune cells, and pharmaceutical composition comprising same
|
CN115485295A
(en)
|
2020-03-10 |
2022-12-16 |
麻省理工学院 |
Compositions and methods for immunotherapy of NPM1 c-positive cancers
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
WO2021216623A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
CA3178670A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Lucas Benjamin HARRINGTON |
Programmable nucleases and methods of use
|
US20240216508A1
(en)
|
2020-06-26 |
2024-07-04 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
GB2617799A
(en)
*
|
2021-02-01 |
2023-10-18 |
Epsilen Bio S R L |
Gene silencing
|
CN117693508A
(en)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
Combination of T cell therapy and DGK inhibitors
|
CA3208944A1
(en)
|
2021-03-22 |
2022-09-29 |
Edith NALBANDIAN |
Method to assess potency of viral vector particles
|
WO2022215982A1
(en)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Guide rna complementary to trac gene and use thereof
|
WO2022232839A1
(en)
|
2021-04-30 |
2022-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for improved production of primary cd34+ cells
|
US20230016422A1
(en)
*
|
2021-06-23 |
2023-01-19 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
KR20240099259A
(en)
|
2021-10-14 |
2024-06-28 |
아스널 바이오사이언시스, 인크. |
Immune cells with co-expressed SHRNA and logic gate system
|
WO2023077149A1
(en)
|
2021-11-01 |
2023-05-04 |
Sigma-Aldrich Co. Llc |
Electroporation enhancers for crispr-cas systems
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
TW202342498A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae fusion glycoproteins
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023201133A1
(en)
|
2022-04-14 |
2023-10-19 |
Board Of Regents Of The University Of Nebraska |
Cell therapy for alzheimer's disease
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
US20240067969A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064606A2
(en)
*
|
2022-09-19 |
2024-03-28 |
Emendobio Inc. |
Biallelic knockout of ctla4
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
CN116539885B
(en)
*
|
2023-07-06 |
2023-09-29 |
上海秤信生物科技有限公司 |
Tumor autoantigen/antibody combination for early detection of breast cancer and application thereof
|